Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- BI Japan Halts Development of Faldaprevir, Calls off Entry into Hepatitis C Field
June 26, 2014
- Nihon Chouzai Reaches Price Settlements with All Wholesalers; Expects to Avoid Reductions in Basic Dispensing Fees
June 25, 2014
- SGLT-2 Inhibitors Vigorously Increase in Anterio’s “Mind Share” Ranking in May
June 25, 2014
- Sanofi-Brand Generics of Diovan, Zometa Hit Shelves in Japan
June 24, 2014
- Diovan, Zometa Authorized Generics Now Available in Japan
June 24, 2014
- Plavix Grabs Top Spot in FY2013 Domestic Ethical Drug Sales Ranking
June 24, 2014
- Prevenar 13 Approved for Use in Elderly: Pfizer Japan
June 24, 2014
- Probe Finds Takeda’s Systematic Involvement in CASE-J Study, No Data Tampering
June 23, 2014
- Blopress AGs Scheduled for Release in Mid-September: ASKA
June 20, 2014
- Kyowa Kirin Starts PI Study of Aβ Peptide Antibody for Alzheimer's Disease in Europe
June 20, 2014
- Takeda Ceases Development of TAK-700 for Prostate Cancer on Lackluster PIII Results
June 20, 2014
- Takeda Launches Zacras Combination Tablets
June 20, 2014
- DSP Now Renamed “Sumitomo Dainippon Pharma” in English
June 19, 2014
- Serious ADRs Reported in Xeljanz EPPV Include Heart Failure, Pneumonia: Prof.
June 19, 2014
- Novartis Begins Global Filings for PV Treatment Ruxolitinib following Positive PIII Results
June 19, 2014
- Ono Calls Off License Pact with German Peer Merck for ONO-4641
June 19, 2014
- Japan Vaccine President and Chairman Swap Posts
June 19, 2014
- Fycompa Meets Primary Endpoints in Patients with PGTC Seizures in PIII Study: Eisai
June 19, 2014
- Takeda UC, CD Treatment Entyvio Goes on Sale in US
June 18, 2014
- Selexipag Meets Primary Endpoint in PIII GRIPHON Study: Nippon Shinyaku
June 18, 2014
ページ
AAV (adeno-associated virus) gene therapies are moving beyond rare diseases into more prevalent conditions, with neovascular, or wet, age-related macular…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…